Nanni Schmitt

7PUBLICATIONS
19CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMedical infection agents (incl. prions)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 30, 2026
Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

|Dec 23, 2025
Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

Jonathan Bobak, Philipp Spohr, Sarah Richter

|Aug 21, 2025
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS.

Nanni Schmitt, Jana-Julia Siegler, Alexandra Beck

|Mar 18, 2023
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.

Qingyu Xu, Alexander Streuer, Johann-Christoph Jann

|Jan 21, 2023
In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies.

Qingyu Xu, Eva Altrock, Nanni Schmitt

|Oct 26, 2021
Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo.

Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov

Pageof 2

Frequent Collaborators

4 joint publications

Alexander Streuer

3 joint publications

Daniel Nowak

2 joint publications

Ali Darwich

2 joint publications

Vladimir Riabov